PrismRA
Rheumatoid Arthritis (predicting anti-TNF response)
CommercialActive
Key Facts
Indication
Rheumatoid Arthritis (predicting anti-TNF response)
Phase
Commercial
Status
Active
Company
About Scipher Medicine
Scipher Medicine is a private, commercial-stage diagnostics company focused on transforming the treatment of autoimmune diseases through precision medicine. Its core asset is the PrismRA blood test, a commercially launched molecular signature test to predict response to anti-TNF therapy in rheumatoid arthritis, which has secured Medicare coverage. The company's foundation is its Spectra AI platform, which analyzes a vast registry of real-world clinico-genomic data to discover biomarkers, guide therapeutic development, and provide commercialization insights, supported by partnerships with pharmaceutical companies like Galapagos and Ionis.
View full company profile